The tumor biopsy specimen was acquired from a Black man (CP-08724), previously diagnosed with low-risk prostate adenocarcinoma (Gleason score 3+3) in his 50s, and had been treated with leuprolide and brachytherapy which had successfully reduced prostate-specific antigen (PSA) (Fig. 3A). This evidence concerns the gene KLK3 and neoplasm.